MTOR and triple-negative breast carcinoma: Regarding the PI3K/mTOR pathway, also indicated by our CMAP exploration, only few clinical trials have tested PI3K and/or mTOR inhibitors in advanced triple negative breast cancer, with published data from one trial so far (i.e., NCT00499603), and with no change in response rate (at 12 weeks) following downregulation of mTOR57.